
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International demonstrated solid growth in its Healthcare Systems & Technologies segment, with year-over-year sales increases of approximately 6% in Q1 2025 and 2% in Q2 2025, alongside projected sales growth of about 4% and 2% in Q3 and Q4 2025, respectively. The company’s strategic acquisition of Hillrom in late 2021 has diversified its product portfolio, enhancing its presence in the hospital equipment market. Additionally, management's implementation of pricing initiatives is expected to yield a positive impact on sales growth of roughly 100 basis points for 2024 and 2025, further contributing to a favorable financial outlook.
Bears say
Baxter International's second-quarter 2025 performance was marked by disappointing results, as sales, margins, and earnings per share fell short of consensus expectations. The company has faced a challenging period from 2021 to 2023 due to both external factors and operational missteps, which have resulted in inconsistent quarterly performances and negative guidance revisions. Additionally, gross margins of 40.7% and operating margins of 15.1% were significantly below consensus estimates, driven by sales softness, manufacturing inefficiencies, and an unfavorable product mix.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares